CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematosus

Affiliations

¹ Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
² Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: crowm@hss.edu.

Comment

David R Fernandez et al. Lancet. 2018.

. 2018 Mar 24;391(10126):1126-1127.

doi: 10.1016/S0140-6736(18)30544-0. Epub 2018 Mar 15.

¹ Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
² Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: crowm@hss.edu.

No abstract available

Comment on

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, Faraone SV, Phillips PE, Perl A. Lai ZW, et al. Lancet. 2018 Mar 24;391(10126):1186-1196. doi: 10.1016/S0140-6736(18)30485-9. Epub 2018 Mar 15. Lancet. 2018. PMID: 29551338 Free PMC article. Clinical Trial.